Supported by the improved availability of vaccines and relatively efficient national immunisation programmes, 2022 is expected to be the year of normalisation as Asean countries shift their focus to economic reopenings.
Against this backdrop, investors need to remain vigilant on Covid-19 developments, say analysts at RHB Group Research. In an Oct 22 note, the analysts highlight that investors have grossly underestimated the impact, duration and resilience of the virus, especially in its ability to mutate into more deadly variants.
